文献速递头颈介入US

OK-432(Picibanil)硬化治疗用于甲状腺术后乳糜漏的治疗

OK-432 (Picibanil) Sclerotherapy for the Treatment of Chyle Leakage After Thyroid Surgery.
PubMed 文献 · Korean J Radiol · 2025-04-29

该回顾性研究纳入2019年1月至2024年12月间12例甲状腺术后乳糜漏并接受Picibanil硬化治疗的患者,中位年龄45.5岁;11例(91.7%)达到临床成功,1例(8.3%)无应答后行胸导管栓塞;中位硬化治疗次数2次(范围1-4次),中位随访35个月(范围10-57个月)未见复发;不良事件为发热(10/12)和局部疼痛(4/12),均自行缓解。作者认为Picibanil硬化治疗可能是甲状腺术后乳糜漏安全有效的微创替代方案。

要点

  • 临床成功需同时满足症状改善、超声示乳糜瘤缩小且无周围组织压迫、引流量<10 mL/天。
  • 12例中11例(91.7%)临床成功,1例(8.3%)无应答后改行胸导管栓塞。
  • 中位硬化治疗2次(范围1-4次),中位随访35个月(范围10-57个月)无复发。

核心结论

  • 作者认为Picibanil硬化治疗可能是甲状腺术后乳糜漏安全有效的治疗方法,可能提供一种微创替代方案,临床成功率高且不良事件轻微可控。

研究设计与样本

  • 回顾性研究,纳入2019年1月至2024年12月间连续12例甲状腺术后乳糜漏接受Picibanil硬化治疗的患者,中位年龄45.5岁。
  • 收集患者人口学资料、临床表现、既往治疗、硬化治疗细节、治疗结局及不良事件。

关键影像表现/征象

  • 超声用于评估乳糜瘤体积缩小及对周围组织的压迫效应,作为临床成功判定标准之一。

诊断标准与关键数值

  • 临床成功定义为同时满足三项标准:1)临床症状和体征改善;2)超声示乳糜瘤体积缩小且无对周围组织的压迫效应;3)引流量<10 mL/天(如适用)。
  • 复发定义为初始临床成功后随访影像显示乳糜漏症状再现或原乳糜瘤部位液体再积聚。
  • 12例中11例(91.7%)达到临床成功,1例(8.3%)无应答后需行胸导管栓塞。

临床应用与阅片要点

  • 作者认为Picibanil硬化治疗可能是甲状腺术后乳糜漏安全有效的微创替代方案,临床成功率高且不良事件轻微可控。
  • 超声可用于评估乳糜瘤体积变化及对周围组织的压迫效应,作为疗效判定的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aimed to evaluate the safety and efficacy of OK-432 (Picibanil) sclerotherapy for the management of chyle leakage following thyroid surgery.

MATERIALS AND METHODS: We retrospectively reviewed the medical records of 12 consecutive patients with chyle leakage who underwent Picibanil sclerotherapy after thyroid surgery between January 2019 and December 2024. The collected data included patient demographics, clinical presentation, prior treatments, sclerotherapy details, treatment outcomes, and adverse effects. Clinical success was defined as fulfillment of all three criteria: 1) Improvement in clinical signs and symptoms, 2) Volume reduction of the chyloma without compressive effects on surrounding tissues on ultrasonography, and 3) Drainage amount of <10 mL/day (if applicable). Recurrence was defined as the reappearance of chyle leakage symptoms or re-accumulation of fluid at the previous chyloma site on follow-up imaging after initial clinical success.

RESULTS: Among the 12 patients (median age: 45.5 years), 11 (91.7%) achieved clinical success. One patient (8.3%) did not respond to treatment and subsequently required thoracic duct embolization. The median number of sclerotherapy sessions was two (range, 1-4). Minor adverse effects, such as fever (10/12) and localized pain (4/12), were observed but resolved without long-term complications. No recurrence was noted during the median post-sclerotherapy follow-up period of 35 months (range: 10-57 months).

CONCLUSION: Picibanil sclerotherapy may be a safe and effective treatment for chyle leakage after thyroid surgery. It may offer a minimally invasive alternative with a high clinical success rate and minor, manageable adverse effects.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Lim H, Choi SI. OK-432 (Picibanil) Sclerotherapy for the Treatment of Chyle Leakage After Thyroid Surgery. Korean J Radiol. 2025. PMID: 40341888. doi:10.3348/kjr.2025.0230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。